Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMILAND-1 early landiolol in STEMI undergoing primary PCI
2025-523676-23-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute ST-segment elevation myocardial infarction (STEMI) and acute coronary syndrome (ACS) comparing Rapibloc arm with Placebo arm (2 arms). Primary endpoint: Feasibility of 24-hour landiolol infusion. Planned start Dec 2025; status: authorised.
02
Drugs
landiolol
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2025-523676-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523676-23-00.